Transcatheter Aortic Valve Implantation (TAVI) Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast - 2019 to 2028

Transcatheter Aortic Valve Implantation (TAVI) Market 

Transcatheter Aortic Valve Implantation (TAVI) is an open cardiac operation that replaces a narrowed aortic valve in a minimally invasive manner. It is employed to treat aortic stenosis. Aortic stenosis is a condition when the aortic valve does not fully open, causing blood flow to be restricted. A huge artery called the aorta delivers blood from the heart to the rest of the body. These high-risk patients are those who are ineligible for surgical aortic valve replacement (SAVR) and cannot be operated on. Older people (those over 75) fall under the high-risk category since having an open heart surgery is too dangerous for them.

The market for transcatheter aortic valve implantation is expanding as a result of factors including rising aortic stenosis prevalence, rising demand for different TAVI treatments, and technological breakthroughs in the TAVI area. Additionally, the development of the geriatric population drives the Transcatheter Aortic Valve Implantation (TAVI) Market because older people are more prone to aortic stenosis. Additionally, the industry is being driven forward by technological developments in the TAVI valve and an increase in public awareness of early detection.

However, the expensive cost of TAVI and strict government requirements for the approval of transcatheter aortic valves, class III medical devices, limit Transcatheter Aortic Valve Implantation (TAVI) Market expansion. In contrast, the market is anticipated to experience a number of growth opportunities over the course of the forecast period due to the use of TAVI systems for new indications, an increase in healthcare spending in emerging economies, and a rise in key players' interest in the transcatheter aortic valve implantation (TAVI) market.

The transfemoral procedure segment dominated the market in 2020, and this trend is anticipated to persist over the forecast period due to favourable outcomes. Due to the longer distance from the aortic valve, there are certain difficulties with this implantation. The conventional Transcatheter Aortic Valve Implantation (TAVI) Market procedure is described as transfemoral implantation, in which the prosthetic valve is inserted through the femoral artery with little anaesthetic. However, some individuals cannot have transfemoral TAVI because they have weak or tiny arteries. Transapical implantation, in which the artificial valve is implanted through the left ventricular apex, is favoured in this situation. Additionally, transaortic implantation is designed for patients with weak femoral arteries and compromised breathing capacity, making them unsuitable for both transapical TAVI procedure as well.